Heart risk showdown: which prostate cancer drug is safer?

NCT ID NCT06650579

First seen Feb 28, 2026 · Last updated May 14, 2026 · Updated 12 times

Summary

This study compares two hormone therapy combinations (leuprolide or relugolix plus abiraterone acetate) in men with advanced prostate cancer who are also getting radiation. The goal is to see which combination causes less harm to the heart, since these treatments can raise blood pressure and worsen heart disease. About 72 men will join, and their heart health will be tracked with CT scans and blood tests over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory Proton Therapy Center

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Emory Saint Joseph's Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Winship at Emory Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.